Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Qyuns Therapeutics CoHKSE:02509 -1.84%9 PB Ratio is 5.19 as of Aug. 16, 2026, which is 31% below its 10-year median of 7.54. GuruFocus rates HKSE:02509 with a GF Score™ of 9/100. The stock has 5 warning signs investors should review. Among 1,220 Biotechnology companies, Qyuns Therapeutics Co ranks worse than 69.51% on this metric.
The historical rank and industry rank for Qyuns Therapeutics Co's PB Ratio or its related term are showing as below:
HKSE:02509'
s PB Ratio Range Over the Past 10 Years
Min: 4.03 Med: 7.54 Max: 30.77
Current: 5.19
During the past 5 years, Qyuns Therapeutics Co's highest PB Ratio was 30.77. The lowest was 4.03. And the median was 7.54.
HKSE:02509's PB Ratio is ranked worse than 69.51% of 1220
companies
in the Biotechnology industry
Industry Median: 2.88
vs HKSE:02509: 5.19
During the past 12 months, Qyuns Therapeutics Co's average Book Value Per Share Growth Rate was 208.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 1.70% per year.
During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of Qyuns Therapeutics Co was 1.70% per year. The lowest was -33.20% per year. And the median was -15.75% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02509 vs VRTX, REGN, RVMD: PB Ratio Comparison
For the Biotechnology subindustry, Qyuns Therapeutics Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Qyuns Therapeutics Co PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Qyuns Therapeutics Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Qyuns Therapeutics Co's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Qyuns Therapeutics Co (HKSE:02509) has a PB Ratio of 5.19 as of Aug. 16, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Qyuns Therapeutics Co and its competitors. This is 31% below median its historical median of 7.54. Over the past decade, Qyuns Therapeutics Co's PB Ratio has ranged from 4.03 to 30.77. According to the industry distribution chart, Qyuns Therapeutics Co ranks #848 out of 1220 companies in the Biotechnology industry, placing it in the top 69.5%.
Is Qyuns Therapeutics Co's PB Ratio too high?
Qyuns Therapeutics Co's current PB Ratio of 5.19 is 31% below median its 10-year median of 7.54. Over the past 10 years, this metric has ranged from a low of 4.03 to a high of 30.77. The Biotechnology industry median PB Ratio is 2.88. Qyuns Therapeutics Co's value of 5.19 is 80.2% above this industry median. Based on the distribution chart, Qyuns Therapeutics Co ranks #848 out of 1220 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Qyuns Therapeutics Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Qyuns Therapeutics Co's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Qyuns Therapeutics Co ranks #848 out of 1220 companies for PB Ratio. This places Qyuns Therapeutics Co in the lower half of its industry. The industry median PB Ratio is 2.88. Qyuns Therapeutics Co's value of 5.19 is 80.2% above this benchmark. Historically, Qyuns Therapeutics Co's own PB Ratio has ranged from 4.03 to 30.77 over the past decade. While the company's 10-year median is 7.54 vs. the industry median of 2.88, Qyuns Therapeutics Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.88, based on 1,220 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Qyuns Therapeutics Co's current PB Ratio of 5.19 is 80.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Qyuns Therapeutics Co and its competitors. For the Biotechnology industry, the median PB Ratio is 2.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Qyuns Therapeutics Co's current PB Ratio is 5.19, which is 31% below median its own 10-year median of 7.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qyuns Therapeutics Co stock overvalued right now?
Qyuns Therapeutics Co (HKSE:02509) has a current PB Ratio of 5.19. The current PB Ratio is 5.19, which is 31% below median its 10-year median of 7.54 and 80.2% above the Biotechnology industry median of 2.88. Qyuns Therapeutics Co's overall GF Score™ is 9/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Qyuns Therapeutics Co (HKSE:02509), the current PB Ratio is 5.19 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Qyuns Therapeutics Co Ltd is a clinical-stage biotech company focused on biologic therapies for autoimmune and allergic diseases, with a self-developed drug pipeline. It has built a pipeline that covers the four disease areas in the field, including skin, rheumatic, respiratory, and digestive diseases. The group is principally engaged in the research and development, manufacturing, and commercialisation of biologic therapies for autoimmune and allergic diseases. Key revenue is generated from the PRC.
9GF Score
Get the complete analysis for HKSE:02509
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02509 has been successfully added to your 
